Yongin, South Korea

Gyeong Min Park

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Gc Cell Corporation. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gyeong Min Park. Retrieved from https://idiyas.com/inventor/gyeong-min-park-vut2es4k

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gyeong Min Park: Innovator in Cell Therapy

Introduction

Gyeong Min Park is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of cell therapy, particularly through his innovative methods for culturing natural killer cells.

Latest Patents

Gyeong Min Park holds a patent for a "Method for culturing natural killer cell, using transformed T cell." This method utilizes genetically modified T cells to effectively proliferate and produce natural killer cells from a smaller amount of source cells. The technique not only enhances the cytolytic activity of natural killer cells but also makes it suitable for various applications in commercializing cell therapy products. The natural killer cells produced through this method can serve as valuable cell therapy products.

Career Highlights

Gyeong Min Park is associated with Gc Cell Corporation, where he continues to advance research in cell therapy. His work has the potential to impact the development of new therapeutic approaches for various diseases.

Collaborations

Some of his coworkers include Bokyung Min and Hyun Ah Kim, who contribute to the innovative environment at Gc Cell Corporation.

Conclusion

Gyeong Min Park's contributions to the field of cell therapy through his patented methods highlight his role as an influential inventor. His work promises to enhance the effectiveness of cell therapy products and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…